Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome

Metabolism: Clinical and Experimental

Volumn 48, Issue 4, 1999, Pages 511-519

  Glueck, C J ^a   Wang, Ping ^b   Fontaine, Robert ^b   Tracy, Trent ^b   Sieve Smith, Luann ^b  

^a Cholesterol Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; TROGLITAZONE;

ADULT; AMENORRHEA; ANOVULATION; ARTICLE; BODY MASS; CLINICAL ARTICLE; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; OVARY CYCLE; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0032937279     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90113-0     Document Type: Article

References (29)

1. Sattar N, Hopkinson ZEC, Greer IA: Insulin-sensitizing agents in polycystic-ovary syndrome. Lancet 351:305-307, 1998
2. Nestler JE, Jakubowicz DJ, Evans WS, et al: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876-1880, 1998
3. Nestler JE, Jakubowicz D: Decrease in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617-623, 1996
4. Velazquez EM, Mendoza SG, Hamer T, et al: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647-654, 1994
5. Velazquez EM, Acosta A, Mendoza SG: Menstrual cychcity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 90:392-395, 1997
6. Velazquez EM, Mendoza SG, Wang P, et al: Metformin therapy is associated with decreased plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 46:454-457, 1997
7. Acbay O, Gundogdu S: Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 65:946-949, 1996
8. Dunaif A, Scott D, Finegood D, et al: The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovarian syndrome. J Clin Endocrinol Metab 81:3299-3306, 1996
9. Ehrmann D, Schneider DJ, Sobel BE, et al: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108-2116, 1997
10. Casimirri F, Biscotti M, Gambineri A, et al: Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. Int J Obes 21:861, 1997 (suppl 2, abstr)
11. Van der Spuy ZM, Dhansay R, Nugent FA: Adjuvant therapy with metformin to improve the therapeutic outcome in anovulatory hyperinsulinaemic women with polycystic ovary syndrome. Hum Reprod 11:167, 1996 (abstr)
12. Ehrmann DA, Cavaghan M, Imperial J, et al: Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrmol Metab 82:524-530, 1997
13. Crave JC, Fimbel S, Lejeune H, et al: Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 80.2057-2062, 1995
14. Morin-Papunen LC, Koivunen RM, Ruokonen A, et al: Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69:691-696, 1998
15. Diamanti-Kandarakis E, Kouli C, Tsianateli T, et al: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138:269-274, 1998
16. Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447, 1961
17. Franks S: Polycystic ovary syndrome: A changing perspective. Clin Endocrinol (Oxf) 31:87-120, 1989
18. Fontaine RN, Gupta A. Wang P, et al: Allele-specific amplification refractory mutation system for genotyping the 4G/5G polymorphism in the promoter region of the plasminogen activator inhibitor-1 gene. J Invest Med 46:A231, 1998 (abstr)
19. Snedecor GW, Cochran WG: Statistical Methods (ed 7). Ames. IA, Iowa State University Press. 1980
20. The Lipid Research Clinics Population Studies Data Book, vol 1. The Prevalence Study. Bethesda, MD, US DHHS. Public Health Service. NIH Publication No. 80-1527, 1980
21. Legro RS, Dunaif A: The role of insulin resistance in polycystic ovary syndrome. Endocrinoiogist 6:307-321, 1996
22. Pasquali R. Filicori M: Insulin sensitizing agents and polycystic ovary syndrome. Eur J Endocrinol 138:253-254, 1998
23. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
24. Wild RA: Cardiovascular disease risks, insulin resistance, and androgen excess. Semin Reprod Endocrinol 12:38-44, 1994
25. Dunaif A: Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Semin Reprod Endocrinol 12:15-20, 1994
26. Burghen GA, Givens JR, Kitabchi AE: Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50:113-116, 1980
27. Toscano V, Bianchi P, Balducci R, et al: Lack of linear relationship between hyperinsulinemia and hyperandrogemsm. Clin Endocrinol (Oxf) 36:197-202, 1992
28. Dahlgren E, Friberg LG, Johannsson S, et al: Endometrial carcinoma. Ovarian-dysfunction - A risk factor in young women. Eur J Obstet Gynecol Reprod Biol 41:143-150, 1991
29. Kiddy DS, Hamilton-Fairley D, Bush A, et al: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36:105-111, 1992